DePuy Orthopaedics launched several new surgical products this week for knee, shoulder and hip revisions.The Johnson & Johnson (NYSE:JNJ) subsidiary accounted for $5.8 billion in sales in 2011, but those sales were offset by $521 million in costs associated with the 2010 recall of its metal-on-metal ASR hip replacement system. That line of products had [...]

Johnson & Johnson’s (NYSE:JNJ) product recalls, litigation and patent battles have taken a toll on the company’s profits in the fourth quarter of 2011.The medical device and pharmaceutical giant, based in New Brunswick, New Jersey, reported one-time charges of $3 billion that include settlements associated with off-marketing allegations over its anti-psychotic drug Risperdal and recalls [...]

Johnson & Johnson (NYSE:JNJ) has lost a court battle over its drug-coated stent patents after a New Jersey federal judge ruled that stents marketed by Boston Scientific (NYSE:BSX) Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) had not infringed stent patents held by the New Brunswick, New Jersey company.Despite the ruling, a Johnson & Johnson spokeswoman said [...]

Current medical news and unique business news for anyone who cares about healthcare.J&J company responds to FDA warning Johnson & Johnson’s (NYSE: JNJ) subsidiary DePuy Orthopaedics received a warning letter from U.S. regulators not to sell joint replacement products without proper approval. The Dec. 8 letter said a federal investigation at DePuy’s Warsaw, Indiana facilities [...]

Johnson & Johnson (NYSE:JNJ) is poised to pay more than $1 billion to the federal government and several states as part of an agreement to end a civil investigation over its marketing of antipsychotic drug Risperdal, according to a report by Bloomberg.The New Brunswick, New Jersey company reached the deal with the U.S. attorney in [...]

Synthes is back in court, this time as the plaintiff in a lawsuit against Stryker Corp. (NYSE: SYK) accusing the Michigan-based medical device company of trying to obtain “an improper competitive advantage.”The complaint,filed in federal court in Philadelphia, also singled out three former sales staff from Synthes’ San Francisco sales unit who resigned from the [...]

Johnson & Johnson (NYSE: JNJ) has issued its latest recall of Motrin, this time from retailers over slow-working tablets and caplets, bringing the number of recalls for this drug alone to six in the past two years, and calling attention to the manufacturing woes faced by the drug maker.J&J subsidiary McNeil’s consumer division recalled 12 [...]

PhaseBio Pharmaceuticals‘ phase I/IIa clinical study for its drug, Glymera, for the treatment of hyperglycemia in patients with type 2 diabetes, met with positive results, according to a release from the company.The single and multiple ascending dose study of 80 subjects in three U.S. study centers assessed the safety, tolerability and pharmacokinetic or PK profile [...]

The Food and Drug Administration has approved Bayer and J& J (NYSE: JNJ) drug Xarelto to treat atrial fibrillation, or abnormal heart rhythm.Earlier this year, Xarelto was approved for use as an anti-coagulant following knee or hip replacement surgery.In September scientists at the FDA recommended that the regulatory agency restrict use of the companies’ blood [...]

Kensey Nash (NASDAQ: KNSY) , an Exton, Pennsylvania-based medical device company focused on regenerative medicine, saw year over year net income decline in the first three months of fiscal year 2012, driven by a $4 million drop in collagen product sales following a change to its contract with St Jude Medical (NYSE: STJ).Net income fell [...]